Stability of RNA virus attenuation approaches

Vaccine

Volumn 29, Issue 12, 2011, Pages 2230-2234

  Kenney, Joan L ^a   Volk, Sara M ^a,b   Pandya, Jyotsna ^a   Wang, Eryu ^a   Liang, Xiaodong ^a   Weaver, Scott C ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b OUR LADY OF THE LAKE UNIVERSITY   (United States)

Author keywords

Alphavirus; RNA viruses; Vaccine stability; Venezuelan equine encephalitis virus

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC STABILITY; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RNA STABILITY; RNA VIRUS; STRAIN DIFFERENCE; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; GENOME, VIRAL; GENOMIC INSTABILITY; MICE; PHENOTYPE; PLAQUE ASSAY; POINT MUTATION; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; VACCINES, ATTENUATED; VIRAL VACCINES; VIRULENCE;

EID: 79951809232     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.055     Document Type: Article

References (41)

1. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27(May (20)):2649-2652.
2. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
3. Jacobs B.L., Langland J.O., Kibler K.V., Denzler K.L., White S.D., Holechek S.A., et al. Vaccinia virus vaccines: past, present and future. Antiviral Res 2009 Oct, 84(1):1-13.
4. Barrett A.D., Teuwen D.E. Yellow fever vaccine: how does it work and why do rare cases of serious adverse events take place. Curr Opin Immunol 2009, 21(June (3)):308-313.
5. Belongia E.A., Naleway A.L. Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res 2003 Apr, 1(2):87-92.
6. Holland J., Spindler K., Horodyski F., Grabau E., Nichol S., VandePol S. Rapid evolution of RNA genomes. Science 1982 Mar 26, 215(4540):1577-1585.
7. Domingo E., Holland J.J. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997, 51:151-178.
8. Drake J.W. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 1993, 90(May (9)):4171-4175.
9. Drake J.W., Holland J.J. Mutation rates among RNA viruses. Proc Natl Acad Sci USA 1999, 96(November (24)):13910-13913.
10. Steinhauer D.A., Holland J.J. Rapid evolution of RNA viruses. Annu Rev Microbiol 1987, 41:409-433.
11. Chumakov K.M., Powers L.B., Noonan K.E., Roninson I.B., Levenbook I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 1991, 88(January (1)):199-203.
12. Evans D.M., Dunn G., Minor P.D., Schild G.C., Cann A.J., Stanway G., et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 1985, 314(April (6011)):548-550.
13. Westrop G.D., Wareham K.A., Evans D.M., Dunn G., Minor P.D., Magrath D.I., et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 1989, 63(March (3)):1338-1344.
14. Kinney R.M., Chang G.J., Tsuchiya K.R., Sneider J.M., Roehrig J.T., Woodward T.M., et al. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5′-noncoding region and the E2 envelope glycoprotein. J Virol 1993, 67(March (3)):1269-1277.
15. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996, 14(March (4)):337-343.
16. Alevizatos A.C., McKinney R.W., Feigin R.D. Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. Am J Trop Med Hyg 1967, 16(November (6)):762-768.
17. McKinney R.W. Venezuelan equine encephalitis. Pan American Health Organization 1972, 243:369-376.
18. Berge T.O., Bankds I.S., Tigertt W.D. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells. Am J Hyg 1961, 73:209-218.
19. McKinney R.W., Berge T.O., Sawyer W.D., Tigertt W.D., Crozier D. Use of an attenuated strain of Venezuelan Equine Encephalomyelitis virus for immunization in man. Am J Trop Med Hyg 1963, 12(July):597-603.
20. Ludwig G.V., Turell M.J., Vogel P., Kondig J.P., Kell W.K., Smith J.F., et al. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am J Trop Med Hyg 2001, 64(January-Febuary (1-2)):49-55.
21. Davis N.L., Brown K.W., Greenwald G.F., Zajac A.J., Zacny V.L., Smith J.F., et al. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 1995, 212(September (1)):102-110.
22. Atasheva S., Wang E., Adams A.P., Plante K.S., Ni S., Taylor K., et al. Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus. Vaccine 2009, 27(July (32)):4309-4319.
23. Paessler S., Fayzulin R.Z., Anishchenko M., Greene I.P., Weaver S.C., Frolov I. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J Virol 2003, 77(17):9278-9286.
24. Wang E., Petrakova O., Adams A.P., Aguilar P.V., Kang W., Paessler S., et al. Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. Vaccine 2007, 25(October (43)):7573-7581.
25. Wang E., Volkova E., Adams A.P., Forrester N., Xiao S.Y., Frolov I., et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008, 26(September (39)):5030-5039.
26. Wang E., Bowen R.A., Medina G., Powers A.M., Kang W., Chandler L.M., et al. Virulence and viremia characteristics of 1992 epizootic subtype IC Venezuelan equine encephalitis viruses and closely related enzootic subtype ID strains. The Am J Trop Med Hyg 2001, 65(July (1)):64-69.
27. Paessler S., Ni H., Petrakova O., Fayzulin R.Z., Yun N., Anishchenko M., et al. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J Virol 2006, 80(March (6)):2784-2796.
28. Kinney R.M., Johnson B.J., Welch J.B., Tsuchiya K.R., Trent D.W. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology 1989, 170(May (1)):19-30.
29. Davis N.L., Willis L.V., Smith J.F., Johnston R.E. In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 1989, 171(July (1)):189-204.
30. Eigen M. Viral quasispecies. Sci Am 1993, 269(July (1)):42-49.
31. Martinez M.A., Carrillo C., Gonzalez-Candelas F., Moya A., Domingo E., Sobrino F. Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies. J Virol 1991, 65(July (7)):3954-3957.
32. Ruiz-Jarabo C.M., Arias A., Baranowski E., Escarmis C., Domingo E. Memory in viral quasispecies. J Virol 2000, 74(April (8)):3543-3547.
33. Codoner F.M., Daros J.A., Sole R.V., Elena S.F. The fittest versus the flattest: experimental confirmation of the quasispecies effect with subviral pathogens. PLoS Pathog 2006, 2(December (12)):e136.
34. de la Torre J.C., Holland J.J. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J Virol 1990, 64(December (12)):6278-6281.
35. Pfeiffer J.K., Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog 2005, 1(October (2)):e11.
36. Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006, 439(January (7074)):344-348.
37. Sanz-Ramos M., Diaz-San Segundo F., Escarmis C., Domingo E., Sevilla N. Hidden virulence determinants in a viral quasispecies in vivo. J Virol 2008, 82(November (21)):10465-10476.
38. Sauder C.J., Vandenburgh K.M., Iskow R.C., Malik T., Carbone K.M., Rubin S.A. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 2006, 350(June (1)):48-57.
39. Ciota A.T., Ngo K.A., Lovelace A.O., Payne A.F., Zhou Y., Shi P.Y., et al. Role of the mutant spectrum in adaptation and replication of West Nile virus. J Gen Virol 2007, 88(March (Pt 3)):865-874.
40. Novella I.S., Ebendick-Corpus B.E. Molecular basis of fitness loss and fitness recovery in vesicular stomatitis virus. J Mol Biol 2004, 342(October (5)):1423-1430.
41. Coffey L.L., Vasilakis N., Brault A.C., Powers A.M., Tripet F., Weaver S.C. Arbovirus evolution in vivo is constrained by host alternation. Proc Natl Acad Sci USA 2008, 105(May (19)):6970-6975.